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Introduction: The magnitude of change in quantitative 18-fluoro-
2-deoxy-glucose (FDG) uptake in the primary tumor after induction
chemotherapy (IC) strongly correlates with the histologic response.
We aimed to investigate the mechanisms that drive persistent FDG
uptake in non-small cell lung carcinoma treated with IC.
Patients and Methods: Baseline and repeat positron emission
tomography using 18-fluoro-2-deoxy-glucose after IC and com-
pletely resected primary tumor after IC was available in 30 patients.
The surgical specimens were quantitatively analyzed for tumor
architecture on hematoxylin and eosin staining. Immunohistochem-
ical staining was assessed for microvessel density, markers of cell
proliferation (Ki-67), hypoxia (HIF-1), extracellular acidification
(CAIX), and p-Akt.
Results: The percentage viable tumor cells and Ki-67 length density
after IC were significantly lower in metabolic responders compared
with nonresponders. Hypoxia-related and acidity-related markers
did not show a significant difference between metabolic responders
and nonresponders.
Conclusions: Tumor response after IC is related to both a decline in
the number of viable tumor cells and FDG consumption. Although
surrogate markers for tumor hypoxia and acidity showed a trend for
correlation with increased glycolysis in pretreated stage IIIA-N2
non-small cell lung carcinoma, these markers did not contribute to
the recognition of metabolic responders versus nonresponders. We
observed that only surrogate markers of cell proliferation correlate
with a metabolic response after IC.
Key Words: Biomarker, FDG-PET, Induction chemotherapy, Non-
small cell lung cancer.
(J Thorac Oncol. 2009;4: 1221–1225)
Features of positron emission tomography using 18-fluoro-2-deoxy-glucose (FDG-PET) in non-small cell lung car-
cinoma (NSCLC) are its accuracy in cancer staging, its
prognostic value, and its capacity to evaluate response to
cancer treatment.1,2 Molecular imaging is increasingly unrav-
eling the phenotypic disease expression in the individual
patient. Elevated glycolysis accompanies several tumor and
microenvironmental characteristics, including increased tu-
mor cell proliferation,3 tumor hypoxia,4 and decreased apo-
ptosis.5 FDG-PET can monitor metabolic tumor response
after induction therapy for malignant disease. Prospective
studies in NSCLC showed that the magnitude in changes of
quantitative 18-fluoro-2-deoxy-glucose (FDG)-uptake of the
primary tumor strongly, but imperfectly, correlate with the
histopathologic response to induction therapy.6,7
Cisplatin is often used in the treatment of NSCLC as
an effective DNA-damaging anticancer drug. Its cytotoxic
property is mainly through binding to nuclear DNA and
subsequent interference with DNA replication and/or nor-
mal transcription mechanisms causing induction of apo-
ptosis. However, not all patients respond to cisplatin.
Multiple mechanisms are involved in hypoxia-induced
chemoresistance, but clinical evidence of its influence on
chemotherapy response is lacking.8,9
The aim of the present study was to investigate the
mechanisms that drive persistent FDG uptake in NSCLC
treated with induction chemotherapy (IC). For that purpose,
we used tumor specimens of patients with stage IIIA-N2
disease who underwent resection after cisplatin-based IC.
The relationship between FDG uptake and morphometric
histologic parameters and expression of several immunohis-
tochemical surrogate biomarkers has been evaluated. Finally,
as full 5-year survival data were available, we correlated
FDG-PET and biomarker results to overall survival.
PATIENTS AND METHODS
Patients
The surgical specimens evaluated were taken from
consecutive NSCLC patients who underwent baseline a state-
of-the-art complete and correct staging including mediasti-
noscopy and FDG-PET. After IC for mediastinoscopy proven
stage IIIA-N2 NSCLC (n  30), patients underwent a repeat
spiral CT scan of the chest and upper abdomen and a repeat
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FDG-PET scan and complete surgical resection with system-
atic mediastinal lymph node dissection at the University
Hospitals Leuven. Adjuvant thoracic radiotherapy was given
to patients with R1/2 resection. IC consisted of three cycles of
Cisplatin, Ifosfamide, and Vindesine.10 The UICC classifica-
tion (TNM, 6th edition, 2002) was used for pathologic stag-
ing. Full 5-year overall survival data were collected for all
patients. Survival time was defined as the time between tumor
diagnosis by histology and death or last follow-up.
Dedicated FDG-PET Scan
A dedicated FDG-PET scan was done baseline before
mediastinoscopy. Interpretation of the FDG-PET was done
prospectively and blinded to surgical pathology data. For the
determination of the standardized uptake value (SUV) of the
primary tumor, volumetric regions of interest were manually
drawn on the transaxial images around the focal FDG uptake
of the primary tumor. The SUV was then automatically
calculated as activity concentration of FDG-uptake divided
by the injected dose/body weight and the pixel with the
maximal SUV was considered the SUVmax. A repeat FDG-
PET on the same PET machine and according to the same
acquisition protocol was performed 3 to 4 weeks after the last
dose of chemotherapy was given to determine the SUVmax of
the primary tumor.
Patients whose tumor SUVmax had decreased by 60%
or more were defined as metabolic responders. This cutoff
point for percentage decrease of SUVmax on the primary
tumor was defined by the median decrease in the whole set of
30 patients and assessed in the authors’ previous work.11
Quantitative Morphology of Tumor
Architecture and Immunohistochemistry
Tumor analysis was performed on histologic sections
stained with hematoxylin and eosin (H&E) from resection
specimens in the files of the pathology department. From
each tumor 2 to 7 H&E sections and corresponding tissue
blocks were available. An H&E section of 4 m thickness,
often the largest one, was chosen for quantitative analysis.
We assumed that it was representative for the entire tumor.
According to the fundamentals of stereology of biologic
material outlined by Weibel,12 the tumor (T) was divided in
compartments of interest which were in this study potentially
related to the investigation of functional metabolic FDG-PET
data for pretreated NSCLC: viable tumor cells (VIA), fibro-
blastic connective tissue (FIB), necrosis, inflammatory inter-
stitium (INF), ‘residu,’ foamy macrophages, and cholesterol
clefts (C). The sum of all compartments represents 100% of
the tumor and discloses also the general tumor architecture.
The proportion of each compartment was obtained by a
conventional morphometric method based on a point-count-
ing technique using a Zeiss light microscope equipped with
an eyepiece containing a reticulated counting frame and
unbiased counting rule.13 The VIA density was counted on a
H&E section using a test line which was randomly located
within a dense zone with viable cancer cell nests and ex-
pressed as number of VIAs per millimetre VIA (expressed as
n cells/mm VIA).
From the original paraffin embedded tissue block se-
lected for quantitative analysis serial sections of 4 m thick-
ness were prepared for immunohistochemical stainings. VIAs
were stained for Ki-67 (a proliferation marker) and endoge-
neous surrogate markers of hypoxia (hypoxia-inducible factor
[HIF]-1 and carbonic anhydrase IX [CAIX]), and phosphor-
Akt (p-Akt; phosphorylation of a serine/threonine kinase that
is implicated in the control of cellular functions such as
transcription and protein synthesis), whereas vessels and
microvessels were stained for with an endothelial marker
CD31. The surface density of the immunostainings for Ki-67,
HIF-1, and p-AKT was assessed using an unbiased counting
frame and unbiased counting rules, corrected for the propor-
tion of VIAs, was transformed into a length density for the
compartment VIA (expressed as n/mm VIA). Similarly, the
surface density of the microvessels was measured and trans-
formed into a length density for the entire tumor (expressed
as n CD31/mm T). The proportion of tumor cells positive for
membranous CAIX was counted. The CAIX length density
per mmVIA (expressed as n CAIX/mm VIA) was obtained by
multiplying this proportion by the VIA density.
KI-67
We used monoclonal mouse antihuman MIB-1 antibod-
ies (Ki-67 antigen DAKO M7240, 1:100, 45 minutes).
CAIX and HIF-1
We used the mouse monoclonal antihuman CAIX an-
tibody M75 (Slovak Academy of Sciences, Bratislava, 1:50,
45 minutes) and the mouse monoclonal antihuman HIF-1
antibody (BD Biosciences Pharmingen, 1:50, overnight).
CD31
To determine the microvessel length density, endothe-
lium of blood vessels on histologic sections was stained with
a CD31 monoclonal antibody (DAKO Cytomation, 1:50, 30
minutes).
p-Akt
We used the polyclonal antihuman phospho-Akt
(Ser473) rabbit antibody (Cell Signaling Technology, Beverly,
MA, 1:50).
Double staining CAIX-CD31
For this purpose, CAIX immunostaining was carried
out without couterstaining. Slides were washed for 15 min-
utes and immunostaining for CD31 was carried out. The
distance from blood vessels marked with CD31 to the start of
membranous CAIX positive tumor cells was assessed using
AxionVision software (ZEISS). Measurements were taken in
three different areas from the three single vessels considered
as shortest to the CAIX expression and finally, the mean of all
distances was calculated. The CAIX-CD31 distance (in m)
was considered a surrogate estimation of the oxygen pressure
at which CAIX positivity starts.
Statistical Analysis
Spearman rank correlation was used to assess the rela-
tionship between continuous variables. The Mann-Whitney U
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test for two groups was applied to assess the association
between continuous variables. Overall survival curves were
calculated with the Kaplan-Meier method and compared by
the log-rank test. All of the statistical analyses were per-
formed with a statistical software package, using GraphPad
Prism version 4.00 for Windows (GraphPad Software, San
Diego, California). Statistical significance was defined as p
values 0.05. All p values were two-sided.
RESULTS
Patient and Tumor Characteristics
Thirty patients (8 females and 22 males; mean age 62
years) with stage IIIA-N2 NSCLC (12 squamous cell carci-
noma, 12 adenocarcinoma, and 6 large cell carcinoma) un-
derwent complete surgical resection after IC and were ana-
lyzed in this report. In this series, no (peri)operative mortality
occurred. For the 30 patients, the median survival time and
5-year survival rate were 36.1 months and 29%, respectively.
Lung cancer recurrence was observed in 86% of deaths.
Biologic Insights: Comparing PET Data to
Immunohistochemical Stainings
Cisplatin-based Pretreated Stage IIIA-N2 NSCLC
The proportion VIA showed a significant correlation
with the percentage decrease of SUVmax after IC (r  0.60
and p  0.0005). No significant correlation was observed
between the percentage decrease in SUVmax and the propor-
tion of necrosis, INF, FIB, foamy macrophages, or C. In total,
60% of the tumors showed any positive nuclear staining for
HIF1, 70% any membranous staining for CAIX, 73% any
positive staining for Ki-67, and 40% any positive staining for
p-Akt. A significant correlation was only observed between
Ki-67 length density and percentage decrease in SUVmax.
Microvessel density or the distance at which positivity for
membranous CAIX expression starts did not correlate with
metabolic response.
Looking at correlations between biomarkers (Table 1), a
significant correlation was found between CAIX and HIF-1
staining, and between Ki-67 and markers of hypoxia. No cor-
relation was seen between microvessel density and cell pro-
liferation (Ki-67) or markers of hypoxia. The surrogate mark-
ers of hypoxia (HIF-1 and membranous CAIX) significantly
correlated with the CAIX-CD31 distance.
Comparing Metabolic Responders and
Nonresponders
The percentage VIAs and Ki-67 length density were
significantly lower and the proportion FIB was significantly
higher in metabolic responders compared with metabolic
nonresponders (Table 2). No significant difference between
metabolic responders and nonresponders was observed for
HIF-1 length density, CAIX length density, CD31 mi-
crovessel length density, p-Akt length density, CAIX-CD31
distance, or proportion INF.
Prognostic Insights: Survival Analysis for PET
and Immunohistochemical Data
Metabolic responders, defined as having 60% de-
crease of SUVmax on primary tumor at FDG-PET, showed a
significant longer survival time compared with metabolic
nonresponders: median survival time 57.5 versus 18.3
months, respectively, and 5-year survival rate 47 versus 13%,
respectively; p  0.009, hazard ratio 0.34 (95%CI 0.12–
0.74). Of all biomarkers studied, only Ki-67 length density, a
surrogate marker for cell proliferation, showed a trend for
TABLE 1. Spearman Rank Correlations
nKI-67a nCAIXa nHIF-1a nCD31b CAIX-CD31c
nCAIXa 0.49 (0.006) — — — —
nHIF-1a 0.59 (0.0006) 0.53 (0.003) — — —
nCD31b 0.05 (0.79) 0.07 (0.72) 0.07 (0.69) — —
CAIX-CD31c 0.34 (0.07) 0.61 (0.0003) 0.55 (0.002) 0.10 (0.59) —
SUVmax (%) 0.51 (0.004) 0.27 (0.15) 0.33 (0.07) 0.22 (0.24) 0.06 (0.59)
p values in brackets.
a Expressed as n/mm VIA.
b Expressed as n/mm T.
c Expressed as distance in m.
CAIX, carbonic anhydrase IX; HIF-1, hypoxia-inducible factor-1; SUVmax, maximal SUV.






% VIA 41 (26–53) 14 (2–27) 0.001
% NEC 5 (2–12) 4 (0–15) 0.63
% FIB 40 (30–49) 57 (40–74) 0.03
% INF 3 (0–8) 3 (1–13) 0.23
% FM  C 3 (0–6) 4 (2–12) 0.18
n cells/mm VIA 60 (45–80) 45 (0–65) 0.046
n Ki-67/mm VIA 16 (10–29) 9 (0–15) 0.02
n CAIX/mm VIA 7 (2–28) 2 (0–26) 0.45
n HIF-1/mm VIA 15 (0–16) 0 (0–17) 0.39
n p-Akt/mm VIA 0 (0–30) 0 (0–18) 0.91
n CD31/mm T 6 (3–8) 5 (0–6) 0.36
Distance CAIX-CD31, m 68 (20–121) 88 (20–140) 0.68
a Mann-Whitney U test; median (IQR, inter quartile range).
VIA, viable tumor cells; NEC, necrosis; FIB, fibroblastic connective tissue; INF,
inflammatory interstitium; FM  C, foamy macrophages  cholesterol clefts; CAIX,
carbonic anhydrase IX; HIF-1, hypoxia-inducible factor-1; p-Akt, phospho-Akt.
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worse prognosis (p 0.10) if a high Ki-67 length density was
observed after IC in the primary tumor.
DISCUSSION
We have noted that stage IIIA-N2 NSCLC patients who
had a survival benefit associated with IC were both PET and
histologic responders.11 Patients with downstaging in the
mediastinal lymph node(s), but without metabolic response
by PET on the primary tumor, did not do better than those
without mediastinal LN downstaging in overall survival.
Chemotherapy-induced morphometric changes in metabolic
responders consist of a significant decrease in VIAs together
with a significant increase in fibrocollagenous stroma. No
difference was seen in necrotic tumor cells or INF between
metabolic responders and nonresponders.
The precise biologic factors associated with response
on FDG-PET after cytotoxic chemotherapy are still unknown.
Uptake of FDG into tumors can be influenced by many
different biologic factors, including glucose utilization, tumor
perfusion, effects of hypoxia, the extend of inflammatory
cells, oncogene expression, effect of apoptosis, and the VIA
fraction. Although the change in FDG uptake is a marker that
significantly but imperfectly correlates with the proportion of
VIAs, other particular processes such as cell proliferation or
hypoxia might help to achieve an even more accurate predic-
tion of response. We observed a highly significant correlation
between the percentage decrease in SUVmax and Ki-67 length
density (Table 1), which was still significant comparing
metabolic responders to nonresponders (Table 2). A trend
was present for correlation between the percentage decrease
in SUVmax and immunohistochemical surrogate markers of
cell hypoxia, HIF-1 (p  0.07), and CAIX (p  0.15),
respectively (Table 1). However, no difference was observed
between metabolic responders and nonresponders for these
surrogate markers neither of hypoxia nor for microvessel
density or CAIX-CD31 distance.
There is no doubt that DNA is the primary target of
cisplatin,14 but there still are wide gaps in our appreciation of
the processes that translate cisplatin-induced nuclear DNA
damage into its characteristic drug-mediated cellular effects
such as caspase-dependent apoptosis resulting in the inability
to take up glucose, inhibition of DNA synthesis, effects on the
cell cycle, and suppression of RNA transcription. By introducing
DNA damage, cytotoxic drugs might exert an inhibitory effect
on transcription in general.15 Cisplatin down-regulates the
expression of HIF-1 protein and inhibits at the post-tran-
scriptional level the expression of the HIF-1 responsive
CAIX in human ovarian cancer cell lines under both nor-
moxia and hypoxia.15 We indeed also observed a significant
correlation between CAIX and HIF-1. A significant corre-
lation between Ki-67 and CAIX or HIF-1 suggests that a
subpopulation of Ki-67 positive cells exists under intermedi-
ate hypoxia.16
Down-regulation of the apoptotic signal is essentially a
universal characteristic of resistance. It has been shown that
PI3K-AKT activation, inhibiting the activation of caspase-3
and caspase-9 and, thus, inhibiting cellular apoptosis,17,18 is
associated with cisplatin resistance in primary cultured lung
cancer cells and human NSCLC tumor tissue samples.19 It has
been shown recently that PI3K-AKT activity is not inhibited
by cisplatin.15 Akt increases cellular glucose uptake and
glycolysis, and has potent oncogenic cell growth and angio-
genic activities.20 These metabolic and antiapoptotic effects
of Akt are independent of HIF-1.20,21 We could not observe a
correlation between p-Akt length density and metabolic re-
sponse (Table 2), maybe as rapid dephosphorylation occurred
during tissue handling at the time of surgery causing a
false-negative immunostaining.22,23 Moreover, monitoring
Ser473 phosphorylation alone may incorrectly assess Akt
kinase activity and evaluation of T308 and S473 phosphory-
lation is probably a better surrogate for Akt activity and more
likely to yield important clinical correlations.24 The most
important limitation to our retrospective immunohistochem-
ical study is that tissue handling and processing was not
standardized at the time of surgery, which could have had an
impact on the interpretation of phosphoproteins or hypoxia-
related immunohistochemical markers (such as HIF-1 and
CAIX).
In conclusion, our results demonstrate that the meta-
bolic response on FDG-PET after cisplatin-based IC in stage
IIIA-N2 NSCLC is associated with a low VIA density and
cellular Ki-67 length density. The inhibitory effects of cis-
platin-based IC on HIF-1 and CAIX expression in the
postinduction resection specimen do not contribute to the
assessment of metabolic tumor response in patients. Meta-
bolic nonresponders show a significant higher level of resid-
ual Ki-67 length density compared with responders, and this
was also associated with a trend for shorter overall 5-year
survival in nonresponders.
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